Wegovy subscription and enforcement

Novo Nordisk started selling Wegovy through a new subscription program on March 31, steering cash-paying patients to a short list of telehealth partners. (novonordisk-us.com, managedhealthcareexecutive.com) The first partners were Ro, WeightWatchers and LifeMD, and Novo Nordisk said Hims & Hers and Sesame were expected to join later. Ro said its plans include 3-, 6- and 12-month prepaid options and can save cash-pay patients up to $1,200 a year on Wegovy pens. (managedhealthcareexecutive.com, ro.co) Novo Nordisk’s current cash-pay terms put starter doses at $199 a month for two fills through June 30, 2026, then $349 a month for standard Wegovy strengths and $399 for Wegovy HD 7.2 mg. NovoCare Pharmacy says one month means one box of four pens. (wegovy.com, novocare.com) Wegovy is the brand-name, Food and Drug Administration-approved semaglutide shot for obesity, and telehealth clinics became a major distribution route during shortages and patchy insurance coverage. Novo Nordisk first linked Ro directly into its distribution push in April 2025, according to Ro. (fda.gov, ro.co) At the same time, federal regulators have been tightening the rules on compounded weight-loss drugs sold online. The Food and Drug Administration said last month that it sent 30 warning letters to telehealth companies over false or misleading claims about compounded glucagon-like peptide-1, or GLP-1, products. (fda.gov) The agency has also posted a broader warning that unapproved semaglutide and tirzepatide products can pose safety risks, and it says it monitors the internet for fraudulent or illegally marketed versions. FDA says compounded drugs are not Food and Drug Administration-approved and should not be treated as interchangeable with approved medicines. (fda.gov) Trade coverage has described the crackdown as building since September 16, 2025, when the Food and Drug Administration issued more than 55 warning letters to online sellers of compounded GLP-1 products. Pharmacy Times reported that the effort initially looked limited, but the newer round of letters signaled a broader enforcement campaign. (pharmacytimes.com, fda.gov) Novo Nordisk has paired the pricing push with legal pressure on sellers it says are offering knockoff semaglutide. In February 2026, the company said it had sued Hims & Hers, and in March it separately said Hims & Hers would distribute approved semaglutide products after a change in that company’s United States GLP-1 business. (novonordisk-us.com) The result is a tighter market built around approved product, selected telehealth channels and manufacturer-set pricing. Patients looking for lower cash prices can now find them inside Novo Nordisk’s network, while regulators and drugmakers press harder on sellers outside it. (novonordisk-us.com, fda.gov)